INBX
Inhibrx Biosciences, Inc.Company Information
- Company Name
- Inhibrx Biosciences, Inc.
- CIK
- CIK0002007919
- Category
- <br>Emerging growth company
- Ticker: Exchange
- INBX: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2836
- SIC Description
- Biological Products, (No Diagnostic Substances)
- Ticker
- INBX
SEC filing data through
Insider Sentiment
- Last purchase
- 2026-09-28
- Last sale
- 2026-09-15
- Shares purchased (TTM)
- 47,000
- Shares sold (TTM)
- 351,000
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 14,321,560
- Shares outstanding
- 15,669,000
- Ownership
- 91.40%
Earnings Market Reaction
- Filing date
- 2026-08-13
- Price on filing date
- —
- 1-month reaction
- 24.90%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nonrelated Party | - | - | 0 | -0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Related Party | - | - | 0 | -0 | 0 | 0 | 0 | 0 | 0 | ||||||
Assets Current | |||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 133 | 162 | 124 | 153 | 187 | 217 | 153 | 196 | 227 | ||||||
| Other Receivables Net Current | 0 | 0 | 0 | 1 | 1 | - | 0 | - | 1 | ||||||
| Prepaid Expense And Other Assets Current | 9 | 9 | 8 | 7 | 6 | 7 | 7 | 10 | 14 | ||||||
| Assets Current | 142 | 171 | 133 | 161 | 194 | 223 | 160 | 207 | 242 | ||||||
| Property Plant And Equipment Net | 3 | 3 | 4 | 4 | 5 | 6 | 6 | 7 | 8 | ||||||
| Operating Lease Right Of Use Asset | 5 | 5 | 6 | 6 | 6 | 7 | 7 | 2 | 2 | ||||||
| Other Assets Noncurrent | 5 | 4 | 4 | 6 | 7 | 7 | 7 | 7 | 7 | ||||||
| Assets | 154 | 184 | 146 | 177 | 212 | 243 | 181 | 223 | 258 | ||||||
Liabilities Current | |||||||||||||||
| Accounts Payable Current | 10 | 9 | 6 | 7 | 8 | 9 | 9 | 12 | 13 | ||||||
| Accrued Liabilities Current | 16 | 15 | 26 | 27 | 28 | 33 | 30 | 30 | 24 | ||||||
| Operating Lease Liability Current | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | ||||||
| Liabilities Current | 28 | 27 | 34 | 36 | 39 | 44 | 41 | 44 | 39 | ||||||
| Long Term Debt Noncurrent | 176 | 175 | 101 | 100 | 99 | 99 | 0 | 0 | 0 | ||||||
| Operating Lease Liability Noncurrent | 3 | 3 | 4 | 5 | 5 | 6 | 6 | 0 | 0 | ||||||
| Liabilities | 207 | 205 | 138 | 141 | 144 | 148 | 47 | 44 | 39 | ||||||
Equity | |||||||||||||||
| Preferred Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 263 | 259 | 254 | 250 | 247 | 244 | 240 | 237 | 234 | ||||||
| Retained Earnings Accumulated Deficit | -316 | -280 | -246 | -213 | -178 | -149 | -106 | -58 | -14 | ||||||
| Stockholders Equity | -53 | -21 | 8 | 37 | 69 | 94 | 134 | 178 | 219 | ||||||
| Liabilities And Stockholders Equity | 154 | 184 | 146 | 177 | 212 | 243 | 181 | 223 | 258 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | - | 0 | 0 | 0 | - | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 120 | 120 | 120 | 120 | 120 | 120 | 120 | 120 | 120 | ||||||
| Common Stock Shares Issued | 15 | 15 | 15 | 14 | 14 | 14 | 14 | 14 | 13 | ||||||
| Shares Outstanding | 15 | 15 | 15 | 14 | 14 | 14 | 14 | 14 | 14 | ||||||
Select a line item above to chart it.
Recent filings
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialInhibrx Biosciences, Inc. (INBX) — SEC Financial Statements & Analysis
Inhibrx Biosciences, Inc. (INBX) is a biological products, (no diagnostic substances) company, incorporated in DE. Inhibrx Biosciences, Inc. trades on Nasdaq as: INBX. Inhibrx Biosciences, Inc. (INBX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-13. Based on that filing, Inhibrx Biosciences, Inc. carries a market cap of $1.48B, a P/E ratio of -10.74x, a P/B ratio of -28.02x, a P/S ratio of 805.98x, an enterprise value of $1.53B, and an EV/EBITDA multiple of -12.16x. On profitability, it posts an operating margin of -9465.46%, a net margin of -10014.23%, a Return on Equity (ROE) of -1773.60%, and a Return on Assets (ROA) of -75.44%. Per share, it reports EPS of $-8.82, diluted EPS of $-8.82, free cash flow per share of $-8.42, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -100.00% year-over-year, net income growth of -43.00% year-over-year, and EPS growth of -43.73% year-over-year. On the balance sheet, it maintains a current ratio of 5.07x, a quick ratio of 4.76x, working capital of $114.15M, a debt-to-equity ratio of -3.91x, a debt ratio of 1.34, an interest coverage ratio of -8.21x, free cash flow of $-131.90M (TTM), and net debt of $42.94M. Figures sourced from SEC EDGAR.
- Market Cap
- $1.48B
- P/E TTM
- -10.74x
- EPS TTM
- $-8.82
- P/B TTM
- -28.02x
- ROE TTM
- -1773.60%
- ROA TTM
- -75.44%
- Debt To Equity
- -3.91x
- Free Cash Flow TTM
- $-131.90M
- Net Revenue TTM Growth 1Y
- -100.00%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Inhibrx Biosciences, Inc. in?
Inhibrx Biosciences, Inc. (INBX) operates in the Biological Products, (No Diagnostic Substances) industry.
What exchange does INBX trade on?
Inhibrx Biosciences, Inc. (INBX) trades on the Nasdaq.
Where is Inhibrx Biosciences, Inc. incorporated?
Inhibrx Biosciences, Inc. is incorporated in DE.
When was Inhibrx Biosciences, Inc. (INBX)'s most recent SEC filing?
Inhibrx Biosciences, Inc. (INBX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-13.
What is INBX's market cap?
Inhibrx Biosciences, Inc. (INBX) has a market capitalization of $1.48B as of 2026-06-30.
What is INBX's EPS (earnings per share)?
Inhibrx Biosciences, Inc. (INBX)'s trailing twelve month EPS is $-8.82 as of 2026-06-30.
What is INBX's ROE (return on equity)?
Inhibrx Biosciences, Inc. (INBX)'s trailing twelve month Return on Equity (ROE) is -1773.60% as of 2026-06-30.
What is INBX's ROA (return on assets)?
Inhibrx Biosciences, Inc. (INBX)'s trailing twelve month Return on Assets (ROA) is -75.44% as of 2026-06-30.
What is INBX's EV/EBITDA?
Inhibrx Biosciences, Inc. (INBX)'s trailing twelve month EV/EBITDA is -12.16x as of 2026-06-30.